Scinai Immunotherapeutics Gains Clearance from Italy for Pincell Acquisition

Scinai Immunotherapeutics Gains Clearance from Italy for Pincell S.r.l. Acquisition

Scinai Immunotherapeutics Ltd., a biopharmaceutical company traded on NASDAQ under the ticker SCNI, is making significant strides in its strategic growth within the biopharmaceutical sector. On June 5, 2025, the company announced that it has received regulatory approval from the Italian government under the Golden Power regulation. This approval is essential for Scinai's planned acquisition of Pincell S.r.l., an Italian biotechnology firm specializing in innovative therapies.

The Golden Power approval signifies the successful completion of a major condition required for the acquisition, thus allowing Scinai to proceed towards finalizing the deal. Scinai's CEO, Amir Reichman, expressed optimism regarding this milestone, highlighting its importance in the broader context of their acquisition strategy. However, he also indicated that while this approval is crucial, it does not mark the end of the journey, as there are still further customary conditions to fulfill before the acquisition can be finalized.

In March 2025, Scinai entered into a binding option agreement to obtain all of Pincell’s share capital and voting rights, which emphasizes the company's commitment to expanding its portfolio of immunotherapy products. One of the key developments from Pincell includes a candidate drug known as PC111, which is a fully human monoclonal antibody targeting the Fas/FasL pathway. This therapeutic candidate is currently under development for severe dermatological conditions like Pemphigus and Stevens-Johnson Syndrome, with promising progress as it has already received the European Medicines Agency’s Orphan Drug Designation for Pemphigus.

Prior to the acquisition, Scinai has been proactive in securing resources to advance its initiatives. The company has submitted a grant application seeking €12 million under the European Funds for a Modern Economy (FENG) program, aimed at funding the next development phase of PC111. An announcement regarding the award decision is anticipated by mid-July to early August 2025, which could further propel Scinai's development efforts.

While Scinai has cleared a critical hurdle with the Italian government approval, the finalization of the acquisition is contingent upon the successful outcome of the grant application and several other customary closing conditions. The company's ambition to expand its offerings aligns with its focus on addressing significant unmet medical needs in the inflammation and immunology fields through innovative therapies.

In conclusion, Scinai Immunotherapeutics' recent regulatory success in Italy marks a pivotal the moment for the company as it seeks to enhance its portfolio and impact in the biopharmaceutical industry. As the healthcare landscape continues to evolve, Scinai’s strategic moves reflect a broader trend in the sector toward consolidation and innovation, particularly in the realms of immunotherapy and biotechnology product development.

For further updates on Scinai Immunotherapeutics and its acquisition of Pincell S.r.l., interested parties can monitor the company’s progress through their official communication channels or visit their website at www.scinai.com.